Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
-
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
-
Roivant Sciences (ROIV) Announces Proposed $150M Share Offering
-
Roivant Sciences Announces Proposed Public Offering of Common Shares
-
Roivant Sciences Announces Proposed Public Offering of Common Shares
-
Roivant Sciences (ROIV) Prices 30M Share Primary and Secondary Offering at $5/sh
-
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
-
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
-
Roivant Sciences (ROIV) Announces Proposed Stock Offering, Size not Disclosed
-
Roivant Sciences Announces Proposed Public Equity Offering
-
Roivant Sciences Announces Proposed Public Equity Offering
-
Cantor Fitzgerald Keeps $15 PT on Roivant Sciences (ROIV), 'Keep It Top Of Mind, Highly Anticipated Phase 3 AD Data Coming 1H23'
-
"VTAMA Has Blockbuster Potential" - Cantor Fitzgerald Bullish on Roivant Sciences (ROIV) Following Dermavant’s Drug Approval
-
UPDATE: Cantor Fitzgerald Starts Roivant Sciences (ROIV) at Overweight
-
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update
-
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update
